JANX250117P55000
- 3.30
- +0.65+24.53%
Janux Therapeutics Newsroom
LifeSci Capital Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $100
Janux Therapeutics Price Target Maintained With a $200.00/Share by Cantor Fitzgerald
Janux Therapeutics Analyst Ratings
BTIG Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $100
BTIG Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Kura Oncology (KURA)
Scotiabank Maintains Janux Therapeutics(JANX.US) With Hold Rating, Raises Target Price to $62
TD Cowen Remains a Buy on Janux Therapeutics Inc (JANX)
Janux Therapeutics Inc's Promising Data and Strategic Advancements Earn a Reiterated Buy Rating
Scotiabank Maintains Sector Perform on Janux Therapeutics, Raises Price Target to $62
Janux Therapeutics Price Target Raised to $91.00/Share From $79.00 by Leerink Partners
Janux Therapeutics Is Maintained at Outperform by Leerink Partners
Scotiabank Raises Price Target on Janux Therapeutics to $62 From $42, Keeps Sector Perform Rating
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Raises Target Price to $70
HC Wainwright & Co. Maintains Buy on Janux Therapeutics, Raises Price Target to $70
Janux Therapeutics Analyst Ratings
Buy Rating Affirmed for Janux Therapeutics Inc. Amid Promising Clinical Data and Strategic Advancements
Janux Therapeutics Initiated at Outperform by Leerink Partners
Leerink Partners Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $79
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70